December 8, 2025BloodOpen Access

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

AKAmy A. KirkwoodCancer Research UK BGBrijesh Gautama VDVismay DeshaniManchester Royal Infirmary

Discussion

Member takes

Implication

Retrospective analysis shows immunoglobulin replacement therapy may reduce infection risk in large B-cell lymphoma patients, suggesting improved outcomes.

Key Points

Overall survival at 2 years was 51.7% with a median follow-up of 24 months, indicating notable risk of non-relapse mortality.
Analysis identified low IgA and IgM as significant predictors of worse outcomes, including progression free survival and non-relapse mortality.
Data from 430 patients receiving CD19 CAR T-cell therapy were collected, focusing on immune parameters and infection rates pre- and post-infusion.
Findings suggest immunoglobulin replacement therapy may confer a protective effect against infections, highlighting the need for further research.

Cite This Study

Kirkwood et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c8 https://doi.org/10.1182/blood-2025-714

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows immunoglobulin replacement therapy may reduce infection risk in large B-cell lymphoma patients, suggesting improved outcomes.

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider